Global Cannabinoid Research Center (GCRC)
GCRC holds five pharmaceutical trademarks. Each represents a research direction and prototype concept available for qualified pharmaceutical partnerships, sponsored development and formulation work.
These marks describe research directions and prototype concepts. They are not approved or marketed medicines. Their names and research areas do not establish clinical efficacy, safety results or regulatory approval.
Every GCRC pharmaceutical mark sits here, apart from consumer products, so partners can see the full research pipeline in one place.
| Mark | Research direction | Stage | Collaboration sought |
|---|---|---|---|
| Prevent® | Oncology and infectious disease | Prototype concept | Preclinical research partners |
| Genevex® | Pain management, spray format, oncology | Prototype concept | Sponsored development, formulation |
| Indole-A™ | Indole alkaloid solutions for oncology and infectious disease | Trademark in development | Research collaboration |
| NANO® | Skin applications, hair growth, oncology, infectious disease | Prototype concept | Preclinical research partners |
| NANO CFP® | Carcinogen free preservative concept | Prototype concept | Formulation and preservative research |
Stages are shown as supplied by GCRC and updated as each program progresses.
Pharmaceutical prototype research in oncology and infectious disease.
Pharmaceutical development in pain management, including a spray format, and oncology.
Indole alkaloid solutions for oncology, infectious disease investigation and broader pharmaceutical development.
Pharmaceutical prototype research involving skin applications, hair growth, oncology and infectious disease.
A carcinogen free preservative concept for pharmaceutical formulation and research. The name describes the design goal and does not establish a tested safety result.
GCRC speaks with research organizations, pharmaceutical developers and sponsors about prototype, preclinical, formulation and sponsored development work.
Tell us about your organization and the mark of interest.
Details are shared under a confidentiality agreement.
We agree the preclinical plan, roles and responsibilities.
Sponsored development, formulation or licensing terms.
No. Prevent®, Genevex®, Indole-A™, NANO® and NANO CFP® are research directions and prototype concepts created for preclinical research. None is an approved or marketed treatment.
Preclinical research is the laboratory stage of development that comes before any testing in people. It explores whether a concept is worth developing further.
No. The pharmaceutical marks are not for sale. GCRC discusses them only with qualified research and development partners.
Pharmaceutical developers, research laboratories, universities, sponsors and licensing partners can contact GCRC to discuss prototype, preclinical, formulation or sponsored development work.
Partners, clients and research collaborators, tell us what you are building.
